Vertex Pharmaceuticals
VRTX
515.02
-5.64
-1.08%
Vertex Pharmaceuticals
US · VRTX
#155 by market cap
Listed 1970
515.02
-5.64
-1.08%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608MT Newswires · 2026/11/4
-
Rating change
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $563 to $725Market Newswire · 2026/11/4
-
Company notice
Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/17
-
Rating change
Vertex Pharmaceuticals Price Target Raised to $626.00/Share From $617.00 by BarclaysDow Jones · 2026/11/5
-
RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600Market Newswire · 2026/11/18
-
Company notice
Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thornberry NancySEC · 2026/11/19
-
Rating change
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $640 From $556MT Newswires · 2026/11/10
-
Rating change
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $620Market Newswire · 2026/11/5
-
Rating change
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $620Market Newswire · 2026/11/5
-
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 YearsBenzinga · 2026/11/14
-
Rating change
UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $640Market Newswire · 2026/11/4
-
Company notice
Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/16
-
Company notice
Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JRSEC · 2026/11/17
-
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$8.37 Million in Common StockMarket Newswire · 2026/11/17
-
Company notice
Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bhatia Sangeeta N.SEC · 2026/11/19
-
Rating change
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $626Benzinga · 2026/11/5
-
Rating change
Vertex Pharmaceuticals Price Target Raised to $570.00/Share From $560.00 by JP MorganDow Jones · 2026/11/4
-
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy RatingMarket Newswire · 2026/11/12
-
Rating change
Vertex Pharmaceuticals Is Maintained at Overweight by BarclaysDow Jones · 2026/11/5
-
H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $641Market Newswire · 2026/11/20
-
Company notice
Vertex Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- Brennan Daniel J.SEC · 2026/10/23
-
Rating change
Vertex Pharmaceuticals Price Target Cut to $660.00/Share From $665.00 by Morgan StanleyDow Jones · 2026/11/4
-
Rating change
Vertex Pharmaceuticals Is Maintained at Overweight by Morgan StanleyDow Jones · 2026/11/4
-
Company notice
Vertex Pharmaceuticals | 8-K: Vertex Reports Third Quarter 2026 Financial ResultsSEC · 2026/11/3
-
Rating change
Vertex Pharmaceuticals Price Target Raised to $725.00/Share From $654.00 by Goldman SachsDow Jones · 2026/11/4
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:21 · For reference only, not investment advice and not tailored to your situation.
Vertex Pharmaceuticals discussion 0 comments